E2 ModeratePreliminaryPEM unclearCross-SectionalPeer-reviewedMachine draft
Preliminary determination of a molecular basis of chronic fatigue syndrome.
McGregor, N R, Dunstan, R H, Zerbes, M et al. · Biochemical and molecular medicine · 1996 · DOI
Quick Summary
Researchers tested the urine of 20 ME/CFS patients and 45 healthy controls to look for chemical differences. They found that ME/CFS patients had different levels of several substances in their urine, particularly one called CFSUM1 and beta-alanine, which were higher in patients with more severe symptoms. These findings suggest ME/CFS may have measurable biological markers that could help identify the condition.
Why It Matters
This study provides early evidence that ME/CFS may have detectable biological markers in urine, which could eventually support objective diagnosis of a condition currently diagnosed only by symptom criteria. Identifying biomarkers is crucial for validating ME/CFS as an organic disease, improving diagnostic accuracy, and potentially guiding future treatment development.
Observed Findings
- CFS patients showed significantly elevated urinary CFSUM1 (P < 0.00003), beta-alanine (P < 0.02), tyrosine (P < 0.02), aconitic acid (P < 0.05), and succinic acid (P < 0.05)
- CFS patients showed significantly reduced urinary alanine (P < 0.005), glutamic acid (P < 0.02), and an unidentified metabolite CFSUM2 (P < 0.0007)
- CFSUM1 and beta-alanine abundances were positively correlated with symptom incidence, severity, and SCL-90-R somatization scores (P < 0.001 and P < 0.00001, respectively)
- Multivariate analysis of urinary metabolite profiles differed significantly between CFS and non-CFS groups (P < 0.004)
Inferred Conclusions
- Urinary metabolite profiles can discriminate CFS patients from healthy controls, with CFSUM1, beta-alanine, and CFSUM2 as the most discriminatory compounds
- The positive correlation between metabolite abundances and symptom severity suggests a molecular basis underlying CFS symptoms
- These findings support the biological reality of CFS and point toward potential biomarkers for disease identification
Remaining Questions
- Are these metabolite changes specific to ME/CFS or do they also occur in other fatigue-associated conditions?
- Does the altered metabolite profile persist over time, and do changes in metabolite levels correlate with symptom fluctuations or treatment response?
What This Study Does Not Prove
This study does not prove that CFSUM1 or beta-alanine cause ME/CFS or that these metabolites are specific to the condition—they may also appear in other illnesses. The cross-sectional design cannot establish whether the metabolite changes precede symptom onset or result from the disease process. The findings require replication in larger, independent cohorts before clinical use.
Tags
Symptom:Fatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.1006/bmme.1996.0012
- PMID
- 8733884
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →